Shifting paradigms for the treatment of ductal carcinoma in situ: Less is more.

Ductal carcinoma in situ is a diverse disease in which only 50% of lesions progress to invasive carcinoma, but unfortunately, all patients receive similar treatment recommendations independent of the disease variability. De-escalation is the philosophy that treatment for this disease should be differentiated based on the likelihood of future progression and recurrence. Four surgical trials are looking at the possibility of removing surgical intervention, the current mainstay of treatment, from the algorithm. Molecular assays have been developed to help differentiate the risk of an ipsilateral breast tumor recurrence and potentially guide the postsurgical utility of radiation therapy. Primary endocrine therapy is also being explored as an alternative to standard local therapy. Ductal carcinoma in situ therapy is a very complicated algorithm that should be discussed and treated through shared decision-making. Copyright © 2023 Elsevier Inc. All rights reserved.

Citation

Candice A M Sauder, Hira Abidi, Richard J Bold. Shifting paradigms for the treatment of ductal carcinoma in situ: Less is more. Surgery. 2023 Jul;174(1):129-130

Mesh Tags

PMID: 37069008

search → result